Pharma & Tech: Nov. 10, 2022
$38,398 for a Single Shot of a Very Old Cancer Drug
By Arthur Allen
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?
Pfizer’s Covid Cash Powers a ‘Marketing Machine’ on the Hunt for New Supernovas
By Arthur Allen
While sales of its covid vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.
Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets
By Patricia Kime
Many of the pharmacies were small, independent operations that had decided not to participate next year because of the lowered reimbursement being offered. But they were surprised by an early dismissal, and some patients with specialized drug needs could face difficulties in the transition.
As Links to MS Deepen, Researchers Accelerate Efforts to Develop an Epstein-Barr Vaccine
By Liz Szabo
Recent leaps in medical research have lent urgency to the quest to develop a vaccine against Epstein-Barr, a ubiquitous virus that has been linked to a range of illnesses, from mononucleosis to multiple sclerosis and several cancers.
What Looks Like Pot, Acts Like Pot, but Is Legal Nearly Everywhere? Meet Hemp-Derived Delta-9 THC
By Eric Berger
The 2018 farm bill that legalized hemp created a loophole for an unregulated copycat of marijuana. A form of delta-9 THC — the psychoactive substance in pot — doesn’t face the same laws and regulations as marijuana because it comes from hemp. The drug is poised to upend the cannabis industry.
California Patients Fear Fallout From Third Dialysis Ballot Measure
By Rachel Bluth
Californians are facing the third statewide dialysis initiative in five years. The dialysis industry is spending tens of millions of dollars to defeat Proposition 29 and is running ads saying the measure would force clinics to close — a message that appears to be resonating with patients.
Shopping for ACA Health Insurance? Here’s What’s New This Year
By Julie Appleby
Consumers may find relief in some key changes made by Congress and the Biden administration, although other issues remain unsettled.
Post-‘Roe,’ Contraceptive Failures Carry Bigger Stakes
By Sarah Varney
Science Friday and KHN ran the numbers on birth control failure. Depending on the contraception method, typical-use error rates can add up to hundreds of thousands of unplanned pregnancies each year.
California’s Proposed Flavored Tobacco Ban Gives Hookah a Pass
By Rachel Scheier
Californians will decide Nov. 8 whether to approve a statewide ban on the sale of flavored tobacco products, including menthol cigarettes. But the measure, known as Proposition 31, exempts hookah tobacco. Anti-smoking activists criticize the carve-out, calling it the latest example of businesses using identity politics to profit from a deadly product.
Readers and Tweeters Take Positions on Sleep Apnea Treatment
KHN gives readers a chance to comment on a recent batch of stories.
KHN’s ‘What the Health?’: Biden Hits the Road to Sell Democrats’ Record
With the midterm elections rapidly approaching, President Joe Biden has taken to the road to convince voters that he and congressional Democrats have delivered for them during two years in power. Among the health issues highlighted by the administration this week are pandemic preparedness and the availability of over-the-counter hearing aids. The president also promised to sign a bill codifying the abortion protections of Roe v. Wade if Democrats maintain control of the House and Senate — even though it’s a long shot that there will be enough votes for that. Sarah Karlin-Smith of the Pink Sheet, Sandhya Raman of CQ Roll Call, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
El vínculo con la esclerosis múltiple impulsa una vacuna contra el virus Epstein-Barr
By Liz Szabo
Los científicos llevan años intentando desarrollar vacunas contra este virus. Sin embargo, recientemente varios avances en la investigación médica han dado más urgencia a la búsqueda y más esperanzas de éxito.